Bionano Genomics Inc. [BNGO] Revenue clocked in at $7.30 million, down -59.91% YTD: What’s Next?

Related

Share

Bionano Genomics Inc. [NASDAQ: BNGO] stock went on an upward path that rose over 0.42% on Friday, amounting to a one-week price decrease of less than -0.94%. The company report on December 3, 2020 that Bionano Genomics Users Present the Saphyr System As a Novel Diagnostic Tool for Hematological Malignancies at ASH 2020.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its Saphyr System for optical genome mapping is being introduced as a novel diagnostic tool for heme malignancies by Dr. Rashmi Kanagal-Shamanna of the MD Anderson Cancer Center at the Annual Meeting of the American Society of Hematology (ASH). With more than 18,000 members from nearly 100 countries, the ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. The annual meeting is being held virtually at hematology.org from December 5-8.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Preceding the annual meeting are a number of scientific workshops which are focused on novel technologies and applications and teaching hematologists about novel and emerging methods in molecular pathology. For the first time, this year Bionano optical genome mapping will be introduced in the session on Novel Diagnostic Genomic Tools by Dr. Rashmi Kanagal-Shamanna, Director of the microarray facility in the molecular diagnostic lab of the University of Texas MD Anderson Cancer Center. Dr. Kanagal-Shamanna will be presenting her work on characterizing the performance and clinical value of Saphyr in patients with Myelodysplastic Syndrome (MDS), a common hematologic malignancy.

Over the last 12 months, BNGO stock dropped by -50.78%. The average equity rating for BNGO stock is currently 1.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $75.82 million, with 153.19 million shares outstanding and 150.85 million shares in the current float. Compared to the average trading volume of 5.00M shares, BNGO stock reached a trading volume of 4351364 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Bionano Genomics Inc. [BNGO]:

Ladenburg Thalmann have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on April 08, 2020, representing the official price target for Bionano Genomics Inc. stock.

The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.03, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 10.39. The Price to Book ratio for the last quarter was 4.52, with the Price to Cash per share for the same quarter was set at 0.12.

BNGO Stock Performance Analysis:

Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.94. With this latest performance, BNGO shares dropped by -11.22% in over the last four-week period, additionally sinking by -4.77% over the last 6 months – not to mention a drop of -50.78% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 44.17, with the RSI for the last a single of trading hit 45.20, and the three-weeks RSI is set at 45.26 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 0.5330, while it was recorded at 0.5090 for the last single week of trading, and 0.5437 for the last 200 days.

Insight into Bionano Genomics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -255.44 and a Gross Margin at +22.46. Bionano Genomics Inc.’s Net Margin is presently recorded at -294.34.

Return on Total Capital for BNGO is now -120.73, given the latest momentum, and Return on Invested Capital for the company is -261.76. Return on Equity for this stock declined to -433.64, with Return on Assets sitting at -108.40. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 555.80. Additionally, BNGO Total Debt to Total Capital is recorded at 84.75, with Total Debt to Total Assets ending up at 66.49.

Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$307,372 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.37.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.

BNGO Stock EPS

With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.

Bionano Genomics Inc. [BNGO] Insider Position Details

There are presently around $4 million, or 5.50% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: VANGUARD GROUP INC with ownership of 5,566,305, which is approximately 1468.977% of the company’s market cap and around 0.06% of the total institutional ownership; BANK JULIUS BAER & CO. LTD, ZURICH, holding 849,999 shares of the stock with an approximate value of $0.42 million in BNGO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.31 million in BNGO stock with ownership of nearly 91.937% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 21 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 6,616,358 shares. Additionally, 10 investors decreased positions by around 1,844,226 shares, while 2 investors held positions by with 183,377 shares. The mentioned changes placed institutional holdings at 8,643,961 shares, according to the latest SEC report filing. BNGO stock had 11 new institutional investments in for a total of 879,973 shares, while 5 institutional investors sold positions of 159,460 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam